BioPharma Dive Publishes Post-PCAC Editorial Coverage Monday July 27, 2026 Framing the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) Two-Day Session as Panel Endorsement of Broader Use of Six of Seven Peptides Despite the Absence of Substantive Human Efficacy or Safety Evidence Supporting Their Benefits, With Capital Now Shifting Toward Peptide-Adjacent Companies With Documented FDA Regulatory Engagement, Well-Defined Clinical Development Strategies, and Scalable Manufacturing Infrastructure Rather Than the Compounding-Pharmacy Gray Market That Has Historically Dominated Distribution
BioPharma Dive published post-PCAC editorial coverage Monday July 27, 2026 framing the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) two-day session outcome as advisory endorsement of broader use of six of seven peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) despite the panel's rejection of substantive human efficacy or safety evidence. The editorial frames the vote as a substantive break with the FDA's traditional science-based standard for compounding-substance eligibility and highlights the substantive shift in venture capital and pharmaceutical industry positioning that has followed. Capital is now flowing toward peptide-adjacent companies with documented FDA regulatory engagement (formal drug-development programs seeking NDA or BLA approval), well-defined clinical development strategies (Phase 1-3 registrational programs), and scalable manufacturing infrastructure (state-licensed compounding pharmacies with quality-control documentation, or FDA-registered 503B outsourcing facilities). The commentary contrasts this trajectory with the compounding-pharmacy gray market that has historically dominated peptide distribution (research-chemical suppliers, offshore pharmacies, and clinics operating outside FDA oversight). BioPharma Dive's framing anchors on the July 23-24 PCAC vote as the trigger for the current investment-cycle inflection, and notes that Merck's July 16, 2026 FDA approval of LIPFENDRA (enlicitide, macrocyclic peptide PCSK9 inhibitor) validates the legitimate-drug-development pathway that peptide-industry commentary has framed as an alternative to the compounding-first commercial strategy.